Metabotropic Glutamate Receptor 5 and 8 Modulate the Ameliorative Effect of Ultramicronized Palmitoylethanolamide on Cognitive Decline Associated with Neuropathic Pain.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
09 Apr 2019
Historique:
received: 12 03 2019
revised: 03 04 2019
accepted: 04 04 2019
entrez: 12 4 2019
pubmed: 12 4 2019
medline: 17 8 2019
Statut: epublish

Résumé

This study investigated whether metabotropic glutamate receptor (mGluR) 5 and 8 are involved in the effect of ultramicronizedpalmitoylethanolamide (um-PEA) on the cognitive behavior and long term potentiation (LTP) at entorhinal cortex (LEC)-dentate gyrus (DG) pathway in mice rendered neuropathic by the spare nerve injury (SNI). SNI reduced discriminative memory and LTP. Um-PEA treatment started after the development of neuropathic pain had no effects in sham mice, whereas it restored cognitive behavior and LTP in SNI mice. 2-Methyl-6-(phenylethynyl) pyridine (MPEP), a selective mGluR5 antagonist, improved cognition in SNI mice and produced a chemical long term depression of the field excitatory postsynaptic potentials (fEPSPs) in sham and SNI mice. After theta burst stimulation (TBS) MPEP restored LTP in SNI mice. In combination with PEA, MPEP antagonized the PEA effect on discriminative memory and decreased LTP in SNI mice. The (RS)-4-(1-amino-1-carboxyethyl)phthalic acid (MDCPG), a selective mGluR8 antagonist, did not affect discriminative memory, but it induced a chemical LTP and prevented the enhancement of fEPSPs after TBS in SNI mice which were treated or not treated with PEA. The effect of PEA on LTP and cognitive behavior was modulated by mGluR5 and mGluR8. In particular in the SNI conditions, the mGluR5 blockade facilitated memory and LTP, but prevented the beneficial effects of PEA on discriminative memory while the mGluR8 blockade, which was ineffective in itself, prevented the favorable action of the PEA on LTP. Thus, although their opposite roles (excitatory/inhibitory of the two receptor subtypes on the glutamatergic system), they appeared to be required for the neuroprotective effect of PEA in conditions of neuropathic pain.

Identifiants

pubmed: 30970677
pii: ijms20071757
doi: 10.3390/ijms20071757
pmc: PMC6480075
pii:
doi:

Substances chimiques

Amides 0
Ethanolamines 0
Grm5 protein, mouse 0
Palmitic Acids 0
Pyridines 0
Receptor, Metabotropic Glutamate 5 0
Receptors, Metabotropic Glutamate 0
metabotropic glutamate receptor 8 0
palmidrol 6R8T1UDM3V
6-methyl-2-(phenylethynyl)pyridine 7VC0YVI27Y

Types de publication

Journal Article

Langues

eng

Références

Eur J Pharmacol. 1999 Oct 15;382(3):151-6
pubmed: 10556665
Neurosci Biobehav Rev. 1999 Dec;23(8):1087-110
pubmed: 10643819
Pain. 2000 Aug;87(2):149-58
pubmed: 10924808
J Neurochem. 2000 Sep;75(3):889-907
pubmed: 10936169
Trends Neurosci. 2000 Oct;23(10 Suppl):S86-91
pubmed: 11052225
Neuropharmacology. 2001 Mar;40(3):319-26
pubmed: 11166324
Clin Neuropharmacol. 2001 Mar-Apr;24(2):65-70
pubmed: 11307040
J Neurosci. 2002 Apr 1;22(7):2660-8
pubmed: 11923431
Eur J Pharmacol. 2002 Mar 29;439(1-3):69-75
pubmed: 11937094
J Neurosci. 2002 Jun 15;22(12):5219-29
pubmed: 12077217
Neurobiol Dis. 2002 Dec;11(3):394-409
pubmed: 12586549
Brain Res. 2004 Jun 25;1012(1-2):190-3
pubmed: 15158178
Eur J Pharmacol. 2004 May 25;492(2-3):169-76
pubmed: 15178361
J Neurosci. 2005 Jul 13;25(28):6539-49
pubmed: 16014715
Eur J Neurosci. 2005 Jul;22(2):425-36
pubmed: 16045496
J Neurosci. 2005 Nov 9;25(45):10520-36
pubmed: 16280590
Eur J Neurosci. 2006 Oct;24(7):2011-20
pubmed: 17040473
Neurosci Lett. 2007 Feb 2;412(3):206-10
pubmed: 17123727
Neurobiol Learn Mem. 2007 Oct;88(3):305-11
pubmed: 17548216
Eur J Pharmacol. 2007 Nov 28;574(2-3):127-32
pubmed: 17765219
Prog Brain Res. 2007;163:43-61
pubmed: 17765711
Pain. 2008 Jul;137(1):112-24
pubmed: 17900808
Pain. 2008 Sep 30;139(1):117-26
pubmed: 18442882
Neuropharmacology. 2008 Sep;55(4):537-45
pubmed: 18533199
J Pharmacol Exp Ther. 2009 Sep;330(3):834-43
pubmed: 19515968
Neuropharmacology. 2009 Mar;56(4):735-40
pubmed: 19705571
Genes Brain Behav. 2010 Feb;9(1):33-44
pubmed: 19740090
Cell Calcium. 2010 Feb;47(2):130-9
pubmed: 20034667
J Psychopharmacol. 2011 Dec;25(12):1720-9
pubmed: 20952455
Prog Neurobiol. 2011 Mar;93(3):385-404
pubmed: 21216272
Mol Pain. 2011 Jan 17;7:7
pubmed: 21241462
Neuropsychopharmacology. 2011 Apr;36(5):979-92
pubmed: 21289602
Curr Pain Headache Rep. 2011 Jun;15(3):215-22
pubmed: 21387163
J Neurosci. 2011 Mar 23;31(12):4687-97
pubmed: 21430167
Biol Psychiatry. 2011 Nov 15;70(10):946-53
pubmed: 21890110
Cereb Cortex. 2012 Nov;22(11):2495-518
pubmed: 22139792
CNS Neurol Disord Drug Targets. 2012 Mar;11(2):148-61
pubmed: 22483283
J Neurosci. 2012 Apr 25;32(17):5747-56
pubmed: 22539837
Expert Opin Ther Pat. 2012 Nov;22(11):1337-52
pubmed: 23009122
Eur J Pain. 2013 Jul;17(6):799-810
pubmed: 23193101
Neuropharmacology. 2013 Apr;67:294-303
pubmed: 23220400
Hippocampus. 2013 May;23(5):352-66
pubmed: 23389958
Neuropharmacology. 2013 Nov;74:135-46
pubmed: 23542080
Front Aging Neurosci. 2013 Jul 09;5:29
pubmed: 23847533
J Neurophysiol. 2014 Jun 1;111(11):2196-209
pubmed: 24304862
Mol Pain. 2013 Dec 09;9:64
pubmed: 24313960
Trends Neurosci. 2014 Mar;37(3):136-45
pubmed: 24485517
Eur J Neurosci. 2014 Feb;39(3):444-54
pubmed: 24494684
Amino Acids. 2014 Jun;46(6):1441-8
pubmed: 24623118
Brain Behav Immun. 2014 Oct;41:65-81
pubmed: 24938671
Int J Mol Sci. 2015 Mar 11;16(3):5555-71
pubmed: 25768340
Pain. 2015 Apr;156 Suppl 1:S11-7
pubmed: 25789427
Int J Neuropsychopharmacol. 2015 May 21;18(11):pyv053
pubmed: 25999589
Mol Brain. 2015 Aug 12;8:47
pubmed: 26260027
Mol Pharmacol. 2016 Nov;90(5):609-619
pubmed: 27338080
J Neurochem. 2017 May;141(4):507-519
pubmed: 27363363
eNeuro. 2016 Aug 08;3(4):
pubmed: 27517090
Front Pharmacol. 2017 Mar 06;8:95
pubmed: 28321191
Scand J Pain. 2016 Jan;10:61-73
pubmed: 28361775
Front Mol Neurosci. 2017 Mar 21;10:79
pubmed: 28377693
J Psychopharmacol. 2017 Jun;31(6):740-749
pubmed: 28440729
J Pain Res. 2017 Sep 21;10:2281-2286
pubmed: 29033604
Pain Res Manag. 2017;2017:8296501
pubmed: 29302197
Neurobiol Dis. 2019 Jan;121:106-119
pubmed: 30266286
Tex Med. 1966 Oct;62(10):76-9
pubmed: 5978642
Trends Neurosci. 1993 Nov;16(11):480-7
pubmed: 7507622
J Neurosci. 1995 Jan;15(1 Pt 1):87-98
pubmed: 7823154
J Neurosci. 1994 Oct;14(10):5793-806
pubmed: 7931545
Neuropharmacology. 1994 Jul;33(7):853-7
pubmed: 7969804
Brain Res Bull. 1993;30(3-4):453-9
pubmed: 8096161
Nature. 1993 May 27;363(6427):347-50
pubmed: 8388549
Nature. 1997 Feb 13;385(6617):630-4
pubmed: 9024660
J Neurosci. 1997 Oct 1;17(19):7503-22
pubmed: 9295396
J Biol Chem. 1998 May 8;273(19):11867-73
pubmed: 9565612
Behav Brain Res. 1998 Sep;95(1):37-45
pubmed: 9754875

Auteurs

Serena Boccella (S)

Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. boccellaserena@gmail.com.

Ida Marabese (I)

Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. ida.marabese@unicampania.it.

Monica Iannotta (M)

Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. monica.iannotta@gmail.com.

Carmela Belardo (C)

Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. carmelabelardo@libero.it.

Volker Neugebauer (V)

Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430-6592, USA. volker.neugebauer@ttuhsc.edu.
Garrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, TX 79430-6592, USA. volker.neugebauer@ttuhsc.edu.
Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center, Lubbock, TX 79430-6592, USA. volker.neugebauer@ttuhsc.edu.

Mariacristina Mazzitelli (M)

Department of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430-6592, USA. mariacristina.mazzitelli@ttuhsc.edu.

Gorizio Pieretti (G)

Department of Plastic Surgery, University of Campania "L. Vanvitelli", 80138 Naples, Italy. gorizio.pieretti@unicampania.it.

Sabatino Maione (S)

Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. sabatino.maione@unicampania.it.

Enza Palazzo (E)

Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy. enza.palazzo@unicampania.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH